USCOM LIMITED — Investor Presentation 2021

Feb 23, 2021

USCOM Strong Growth, Bright Future.

H1 FY21 Investor Presentation

Prof. Rob Phillips

24[th] February 2021

ASX: UCM

==> picture [222 x 329] intentionally omitted <==

----- Start of picture text -----

We are proud of the
contributions we have
delivered to global health
care over the last 20 years,
saving lives and improving
the understanding of
diseases.
----- End of picture text -----

“

Uscom continues its mission to create life saving non-invasive cardiovascular and to care pulmonary technologies improve of diseases which are responsible for more than 75% of all global mortality. Developing world leading devices for global markets to create a strongly innovative and profitable global medical technology leader. Prof. Rob Phillips

”

Strong growth, bright future.

USCOM

ASX Listed

Premium global cardiovascular and pulmonary medical technology

Patented Apex Technologies World leading digital technologies in cardiac, vascular and pulmonary medicine

High Growth and High Margins Rapid growth of Revenue, Sale and Cash Flow for H1 FY21

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Cash Flow Positive with Profit

Record Operating Cash Inflow China and Europe Profit

Global Vision and Ambitions

Operations in Sydney, Singapore, Beijing, Budapest Offices in Auckland, London, LA

New Products

Expanding global operations 8 new products in 4 major markets

Strong growth, bright future.

GLOBAL EXPANSION

• London • Beijing • Budapest • LA Operations Sydney • Singapore Singapore Beijing Budapest Offices • Auckland London LA

• Singapore • Sydney • Auckland

China Embedded, Globally Diversified Poised for growth, and hedged for politics and currency

==> picture [100 x 133] intentionally omitted <==

==> picture [89 x 127] intentionally omitted <==

==> picture [105 x 126] intentionally omitted <==

Uscom Global

==> picture [92 x 126] intentionally omitted <==

==> picture [86 x 124] intentionally omitted <==

==> picture [90 x 126] intentionally omitted <==

Smart & Capable

==> picture [103 x 129] intentionally omitted <==

==> picture [100 x 128] intentionally omitted <==

==> picture [95 x 126] intentionally omitted <==

Rob Phillips Nick Schicht Teresa Guo Lucy Lu Scott Huang Denise Pater Rik Denicke George Ferenczi Leo Luo

==> picture [95 x 133] intentionally omitted <==

==> picture [101 x 132] intentionally omitted <==

==> picture [93 x 129] intentionally omitted <==

==> picture [101 x 128] intentionally omitted <==

==> picture [95 x 129] intentionally omitted <==

==> picture [97 x 126] intentionally omitted <==

==> picture [96 x 127] intentionally omitted <==

==> picture [94 x 125] intentionally omitted <==

==> picture [93 x 126] intentionally omitted <==

Scarlett Zhang Szabolcs Reichardt Richard Scott Zsofia Kertesz

Crystal Lin Daniel Gizella

Curt Grosse Andrea Marosan

Susanna Sun

==> picture [98 x 132] intentionally omitted <==

==> picture [93 x 134] intentionally omitted <==

==> picture [95 x 131] intentionally omitted <==

==> picture [96 x 130] intentionally omitted <==

==> picture [91 x 130] intentionally omitted <==

==> picture [83 x 129] intentionally omitted <==

==> picture [87 x 129] intentionally omitted <==

==> picture [88 x 127] intentionally omitted <==

==> picture [90 x 125] intentionally omitted <==

==> picture [97 x 127] intentionally omitted <==

Antonio Ferrario Uzair Khyshzai Catherine Gao Lebron Wei Georgia Manton-Hall Hagay Gilad George Tang Attila Metyko Kevin Badin Tamas Vitrai

==> picture [37 x 37] intentionally omitted <==

H1 20 v H1 21

2021:

H1 RESULTS

==> picture [315 x 406] intentionally omitted <==

----- Start of picture text -----

H1 20 H1 21
↑ 153%
↑ 187%
3.00
2.81
2.77
↑ 232%
2.50
2.30
2.00
1.50
1.11
0.96
1.00
↑ $1.14M 0.68
0.50 0.39
0.00
Cash flow Sales Rev+Income Receipts
-0.50
-0.75
-1.00
Strong growth, bright future.
$M AUD
----- End of picture text -----

ASX:UCM

• Sale of Goods $2.30M up 232%

• Revenue and Income $2.77M up 187%

• Receipts from Customers

$2.81M up 153%

• Net cash flow up $1.14M

• CY20 Revenue and Income

$6.09M up 95% from $3.12M  CY20 Cash $2.3M up $0.8M pa

==> picture [37 x 37] intentionally omitted <==

2021: TREND RESULTS

UCM Total Receipts

$6.0

==> picture [365 x 368] intentionally omitted <==

----- Start of picture text -----

$6.00
$5.00
$4.60
$4.00
$3.64
$3.50
$2.94
$3.00 $2.86
$2.04
$2.00
$1.38
$1.01
$1.00 $0.86
$0.00
2012 2013 2014 2015 2016 2017 2018 2019 2020 CY2020
H1 FY21 and 9 prior years
$M AUD
----- End of picture text -----

ASX:UCM

 Growth Trend Continues

 CY20 $6.09m up 95%

 CY20 cash inflow $0.8M

Strong growth, bright future.

2020: REGIONAL AND PRODUCT SALES

==> picture [37 x 37] intentionally omitted <==

ASX:UCM

==> picture [590 x 321] intentionally omitted <==

• USCOM 1A - lead product

• China - major Uscom market

 BP+ and SpiroSonic sales will increase as regulatory approvals are received in China, Europe, SE Asia and the US.

Strong growth, bright future.

==> picture [162 x 161] intentionally omitted <==

U S C O M 1 A

USCOM 1A software

Uscom Advanced Haemodynamic APP Heart failure, hypertension, sepsis, fluid

==> picture [270 x 168] intentionally omitted <==

BP+ Reporter Hypertension, vascular health

==> picture [4 x 4] intentionally omitted <==

USCOM PRODUCTS

==> picture [59 x 49] intentionally omitted <==

==> picture [84 x 22] intentionally omitted <==

----- Start of picture text -----

Blue Sky
----- End of picture text -----

==> picture [120 x 36] intentionally omitted <==

----- Start of picture text -----

Uscom eHealth Ecosystem
----- End of picture text -----

==> picture [59 x 49] intentionally omitted <==

==> picture [98 x 34] intentionally omitted <==

----- Start of picture text -----

Blue Sky
Uscom eHealth Ecosystem
----- End of picture text -----

==> picture [188 x 135] intentionally omitted <==

==> picture [153 x 46] intentionally omitted <==

SpiroReporter MyAIR APP Asthma, COPD, OLD and COVID

==> picture [264 x 174] intentionally omitted <==

VENTITEST-S Ventilator testing

MASSIVE GLOBAL MARKETS

==> picture [40 x 40] intentionally omitted <==

==> picture [33 x 34] intentionally omitted <==

U S C O M 1 A

==> picture [61 x 36] intentionally omitted <==

==> picture [113 x 34] intentionally omitted <==

==> picture [134 x 33] intentionally omitted <==

==> picture [251 x 25] intentionally omitted <==

==> picture [173 x 24] intentionally omitted <==

==> picture [369 x 25] intentionally omitted <==

==> picture [212 x 25] intentionally omitted <==

==> picture [401 x 33] intentionally omitted <==

----- Start of picture text -----

0 10 20 30 40 50
$ USD Billion
----- End of picture text -----

Massive Clinical Markets

• USCOM1A: ~USD $32 billion by 2025

• • BP+: ~USD 22 billion by 2025

• SpiroSonic: ~USD 47 billion by 2025

• • VentiTest: ~USD 27 billion by 2027 • Total Markets - $128 billion by 2027

Premium Medical Markets

• Cardiac

• Vascular

• Pulmonary

USCOM 1A

https://drug-dev.com/heart-failure-market-to-soar-to-11-8-billion-by 2025/#:~:text=The%20heart%20failure%20market%20is,research%20and%20consulting%20firm%20GlobalData. https://www.grandviewresearch.com/industry-analysis/pulmonary-arterial-hypertension-market#:~:text=hypertension%20market%20growth%3F-,b.,USD%209.39%20billion%20by%202027 https://www.grandviewresearch.com/industry-analysis/sepsis-diagnostics-market

https://www.grandviewresearch.com/industry-analysis/heat-transfer-fluids-market#:~:text=Report%20Overview,4.9%25%20from%202020%20to%202027 BP+

https://www.grandviewresearch.com/industry-analysis/pulmonary-arterial-hypertension-market#:~:text=hypertension%20market%20growth%3F-,b.,USD%209.39%20billion%20by%202027. https://www.marketsandmarkets.com/Market-Reports/interventional-cardiology-peripheral-vascular-devices-market-790.html

VentiTest

https://www.globenewswire.com/news-release/2020/04/14/2015758/0/en/Ventilator-Market-To-Reach-USD-26-66-Billion-By-2027-Reports-and-Data.html

SpiroSonic

https://www.fortunebusinessinsights.com/industry-reports/asthma-treatmentmarket-

101039#:~:text=KEY%20MARKET%20INSIGHTS,4.5%25%20during%20the%20f orecast%20period.

https://drug-dev.com/copd-market-set-to-hit-14-1-billion-by2025/#:~:text=The%20chronic%20obstructive%20pulmonary%20disease,accordin g%20to%20research%20and%20consulting https://www.grandviewresearch.com/press-release/global-respiratory-diseasetesting-diagnostics-market

• Ventilator Calibration

==> picture [48 x 49] intentionally omitted <==

2021 GROWTH DRIVERS

==> picture [97 x 163] intentionally omitted <==

New Products

More Distributors

• SpiroSonic and BP+ approvals for China SE Asia and US

• Uscom China

• SE Asia

• VENTITEST and VENTITEST-S sales

• New European and US distribution models

• Blue Sky eHealth Ecosystem – recurrent digital cloud based revenues

Sales Growth

• China strong

• Europe and US emerging

• SE Asia HQ

Market Share

• Massive markets

• Heart failure, hypertension, sepsis, fluid management,

• vascular diseases, asthma, COPD, COVID.

Strong growth, bright future.

SUMMARY

==> picture [48 x 47] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [42 x 42] intentionally omitted <==

==> picture [47 x 47] intentionally omitted <==

High organic Superior quality World leading devices Rapidly growing revenue growth business model and quality brands fundamentals Rare combination of Increasing cash reserves Imminent new Debt free quality, growth and revenues value

Strong growth, bright future.

==> picture [178 x 48] intentionally omitted <==

VALUE INVESTORS: UCM

==> picture [37 x 37] intentionally omitted <==

“Total receipts up 600% over 8 years, share price unchanged.”

==> picture [379 x 343] intentionally omitted <==

----- Start of picture text -----

$6.0
$6.00
Revenue and Income 8yrs
$5.00
$4.60
$4.00
$3.64
$3.50
$2.94
$2.86
$3.00
$2.04
$2.00
$1.38
$1.01
$0.86
$1.00
$0.00
2012 2013 2014 2015 2016 2017 2018 2019 2020 CY2020
$M AUD
----- End of picture text -----

Share Price 8yrs

==> picture [545 x 138] intentionally omitted <==

Strong growth, bright future.

CONCLUSION

“Growing fundamentals has never been more important to value investors”

“ We continue driving strong growth fundamentals and accumulating cash, while investing in expanded international operations and new subsidiaries, and finalising multiple international regulatory approvals for new products and new revenue .”

Prof. Rob Phillips CEO

Strong growth, bright future.

USCOM Strong Growth, Bright Future

H1 FY21 Investor Presentation

Prof. Rob Phillips

24[th] February 2021

ASX: UCM